Zevra Therapeutics, Inc. (ZVRA) Ownership
ZVRA ownership summary
as of October 17, 2026- Institutions
- 77.6% of shares outstanding
- Insiders
- 1.31% of shares outstanding
- Shares outstanding
- 59.4M
- Float
- 53.9M shares available to trade
- Short interest
- 12.17% 7.1M shares short
- Days to cover
- 7.45 short interest up 24.5% vs prior month
- Institutions 77.64%
- Insiders 1.31%
- Other investors 21.05%
ZVRA top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | BlackRock Inc | 8.60% | 5.1M | $50.8M | +652,395 (+14.6%) | June 30, 2026 |
| 2 | FMR Inc | 8.28% | 4.9M | $48.9M | +1.7M (+53.0%) | June 30, 2026 |
| 3 | Woodline Partners LP | 8.06% | 4.8M | $47.6M | +1.3M (+38.7%) | June 30, 2026 |
| 4 | Nantahala Capital Management, LLC | 6.05% | 3.6M | $35.7M | +1.1M (+42.5%) | June 30, 2026 |
| 5 | Vanguard Capital Management, LLC | 4.44% | 2.6M | $26.2M | +169,582 (+6.9%) | June 30, 2026 |
| 6 | State Street Corp | 2.83% | 1.7M | $16.7M | +120,430 (+7.7%) | June 30, 2026 |
| 7 | Geode Capital Management, LLC | 2.59% | 1.5M | $15.3M | +169,079 (+12.3%) | June 30, 2026 |
| 8 | D. E. Shaw & Co LP | 2.20% | 1.3M | $13.0M | +460,492 (+54.4%) | June 30, 2026 |
| 9 | Qube Research & Technologies | 2.09% | 1.2M | $12.3M | +399,024 (+47.4%) | June 30, 2026 |
| 10 | Morgan Stanley - Brokerage Accounts | 2.03% | 1.2M | $12.0M | +11,613 (+1.0%) | June 30, 2026 |
| 11 | Legal & General Group PLC | 2.02% | 1.2M | $11.9M | +38,578 (+3.3%) | June 30, 2026 |
| 12 | 683 Capital Management LLC | 1.64% | 975K | $9.7M | +70,000 (+7.7%) | March 31, 2026 |
| 13 | Dimensional Fund Advisors, Inc. | 1.61% | 959K | $9.5M | +404,034 (+72.8%) | June 30, 2026 |
| 14 | Royce & Associates, LP | 1.49% | 883K | $8.8M | −106,016 (−10.7%) | June 30, 2026 |
| 15 | Kingdon Capital Management LLC | 1.31% | 775K | $7.7M | — | June 30, 2026 |
| 16 | Retirement Planning Co of New England, Inc. | 1.07% | 634K | $6.3M | −16,738 (−2.6%) | June 30, 2026 |
| 17 | Jupiter Topco LLC | 1.03% | 613K | $6.1M | +613,403 (0.0%) | June 30, 2026 |
| 18 | Arrowstreet Capital Limited Partnership | 1.01% | 597K | $5.9M | +597,162 (0.0%) | June 30, 2026 |
| 19 | The Goldman Sachs Group Inc | 0.92% | 546K | $5.4M | −197,573 (−26.6%) | June 30, 2026 |
| 20 | Vanguard Portfolio Management, LLC | 0.91% | 541K | $5.4M | +74,806 (+16.0%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 16 holders added 7.9M shares and 3 cut 320K.
ZVRA top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Fidelity Contrafund | 4.95% | 2.9M | $29.2M | −960 (−0.0%) | August 31, 2026 |
| 2 | Vanguard MStar Total Stk Mkt Idx Invest | 3.20% | 1.9M | $18.9M | — | August 31, 2026 |
| 3 | iShares Russell 2000 ETF | 2.56% | 1.5M | $15.1M | −17,536 (−1.1%) | September 30, 2026 |
| 4 | State Street® SPDR® S&P® PhrmctlsETF | 1.24% | 735K | $7.3M | −9,134 (−1.2%) | September 30, 2026 |
| 5 | Janus Henderson Small/Md Cp Gr Alpha ETF | 1.19% | 705K | $7.0M | +31,613 (+4.7%) | September 30, 2026 |
| 6 | Fidelity Small Cap Index | 1.08% | 644K | $6.4M | +5,611 (+0.9%) | July 31, 2026 |
| 7 | Fidelity Contrafund K6 | 1.06% | 628K | $6.2M | −1,532 (−0.2%) | August 31, 2026 |
| 8 | iShares Biotechnology ETF | 0.78% | 464K | $4.6M | −3,512 (−0.8%) | September 30, 2026 |
| 9 | International Biotechnology Ord | 0.74% | 439K | $4.4M | −167,121 (−27.6%) | June 30, 2026 |
| 10 | iShares Russell 2000 Value ETF | 0.64% | 379K | $3.8M | +574 (+0.2%) | September 30, 2026 |
| 11 | Swedbank Robur Fokus | 0.61% | 361K | $3.6M | +52,700 (+17.1%) | August 31, 2026 |
| 12 | Vanguard Russell 2000 ETF | 0.57% | 338K | $3.4M | +7,603 (+2.3%) | August 31, 2026 |
| 13 | Fidelity Extended Market Index | 0.49% | 291K | $2.9M | −6,174 (−2.1%) | August 31, 2026 |
| 14 | Royce Small-Cap Trust | 0.48% | 286K | $2.8M | −25,152 (−8.1%) | June 30, 2026 |
| 15 | FTF Royce US Smaller Companies W Acc | 0.44% | 260K | $2.6M | −57,561 (−18.1%) | June 30, 2026 |
| 16 | Royce Small-Cap Fund Invmt | 0.42% | 251K | $2.5M | −19,735 (−7.3%) | June 30, 2026 |
| 17 | Janus Henderson Small Cap Gr Alpha ETF | 0.42% | 251K | $2.5M | +10,703 (+4.5%) | September 30, 2026 |
| 18 | Principal US Small Cap ETF | 0.42% | 247K | $2.5M | +122 (+0.0%) | September 30, 2026 |
| 19 | Invesco Dorsey Wright Healthcare MomtETF | 0.40% | 237K | $2.4M | −1,572 (−0.7%) | September 30, 2026 |
| 20 | Inspire Fidelis Multi Factor ETF | 0.35% | 210K | $2.1M | — | September 30, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
ZVRA insider transactions
latest 9| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-03 | Joshua Schafer | Sell | $9.19 | 10,500 | $96,495 |
| 2026-02-03 | Timothy J Sangiovanni | Sell | $9.18 | 3,000 | $27,540 |
| 2026-02-02 | Neil F Mcfarlane | Sell | $9.38 | 91,000 | $853,580 |
| 2026-01-30 | Adrian W Quartel | Sell | $8.83 | 4,533 | $40,026 |
| 2026-01-30 | Joshua Schafer | Sell | $8.83 | 3,375 | $29,801 |
| 2026-01-30 | Timothy J Sangiovanni | Sell | $8.82 | 1,750 | $15,435 |
| 2025-10-10 | Neil F Mcfarlane | Sell | $10.82 | 19,500 | $210,990 |
| 2025-09-12 | Tamara A Favorito | Buy | $7.79 | 3,175 | $24,733 |
| 2025-08-19 | John B Bode | Buy | $9.16 | 5,000 | $45,800 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
ZVRA shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns ZVRA
Institutional investors own 77.6% of Zevra Therapeutics's shares and insiders 1.31%. The largest holder is BlackRock Inc with 8.60% of the shares (5.1M), as of June 30, 2026. Among the top 20 institutions, 16 added shares and 3 reduced their stake in the latest filings. Short interest is 12.17% of the float, or 7.45 days of average trading volume. The share count rose 7,344.4% since 2014.
Related: ZVRA analyst forecast, ZVRA key metrics. See the ZVRA stock overview for the latest quote and news.
ZVRA ownership FAQ
Who owns the most Zevra Therapeutics stock?
The largest shareholders of Zevra Therapeutics are BlackRock Inc (8.60%), FMR Inc (8.28%), Woodline Partners LP (8.06%), Nantahala Capital Management, LLC (6.05%), Vanguard Capital Management, LLC (4.44%).
What percentage of Zevra Therapeutics is owned by institutions?
Institutions hold 77.6% of Zevra Therapeutics's shares outstanding; insiders hold 1.31%.
Which funds own Zevra Therapeutics?
The largest fund holders of Zevra Therapeutics are Fidelity Contrafund (4.95%), Vanguard MStar Total Stk Mkt Idx Invest (3.20%), iShares Russell 2000 ETF (2.56%), State Street® SPDR® S&P® PhrmctlsETF (1.24%), Janus Henderson Small/Md Cp Gr Alpha ETF (1.19%).
What is Zevra Therapeutics's short interest?
7.1M shares of Zevra Therapeutics were sold short, 12.17% of the float; at the average daily volume it would take 7.45 days to cover.
Are insiders buying or selling Zevra Therapeutics?
Of the latest 9 reported insider transactions in Zevra Therapeutics (since August 19, 2025), 2 were purchases and 7 were sales.
How many shares of Zevra Therapeutics are outstanding?
Zevra Therapeutics has 59.4M shares outstanding, of which 53.9M are in the public float.